Stanford Medcast Episode 43: Hot Topics Mini-Series - Stem Cell Therapy in Multiple Sclerosis

Tuesday, June 21, 2022, 12:00 AM - Saturday, June 21, 2025, 12:00 AM PST

Today's episode includes a discussion with Dr. Jeffrey Dunn who serves as the Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology within the Department of Neurology & Neurological Sciences at Stanford University. The discussion includes an overview of the different types of stem cells, as it relates to Multiple Sclerosis (MS), some of the ways researchers are considering using stem cell therapy to treat MS, and the limitations of disease modifying treatments that stem cell therapy could help address. Advice will also be provided to clinicians whose patients are asking about stem cell therapy and when it will be available to them. This session focuses on the knowledge gaps around the risks and benefits of stem cell therapy and the ongoing research taking place to bring this therapeutic option from bench to bedside.

AMA PRA Category 1 Credits™ (0.50 hours), Non-Physician Participation Credit (0.50 hours)

1. Review the different types of stem cells and their potential impact on treating relapsing MS.
2. Explore the ongoing research and clinicial trials for stem cell therapy.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Credit Designation 
American Medical Association (AMA) 
Stanford Medicine designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credits^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require accommodations, please contact the CME Conference Coordinator.

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: https://laneguides.stanford.edu/multicultural-health

References/Bibliography
1.Genc, B., Bozan, H.R., Genc, S., Genc, K. (2018). Stem Cell Therapy for Multiple Sclerosis. In: Pham, P. (eds) Tissue Engineering and Regenerative Medicine. Advances in Experimental Medicine and Biology, vol 1084. Springer, Cham. https://doi.org/10.1007/5584_2018_247
2.National Multiple Sclerosis Society. (n.d.). Stem Cells in MS. Retreived June 17, 2022 from https://www.nationalmssociety.org/Research/Research-News-Progress/Stem-Cells-in-MS
3.Smith, J. A., Nicaise, A. M., Ionescu, R. B., Hamel, R., Peruzzotti-Jametti, L., & Pluchino, S. (2021). Stem Cell Therapies for Progressive Multiple Sclerosis. Frontiers in cell and developmental biology, 9, 696434. https://doi.org/10.3389/fcell.2021.696434
4.Uccelli, A., Laroni, A., & Freedman, M. S. (2013). Mesenchymal stem cells as treatment for MS – progress to date. Multiple Sclerosis Journal, 19(5), 515 -519. 

For activity related questions, please contact
     Email: [email protected]

For CME general questions, please contact 
     Email: [email protected]

Mitigation of Relevant Financial Relationships

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.

There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity, except those listed in the table below. All of the relevant financial relationships listed for these individuals have been mitigated.

This CME Activity is supported in by an educational grant from Novartis Pharmaceuticals Corporation.